We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Black Diamond (BDTX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Black Diamond is a member of the Medical sector. This group includes 976 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Black Diamond is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BDTX's full-year earnings has moved 37.3% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, BDTX has returned 29% so far this year. In comparison, Medical companies have returned an average of -3%. As we can see, Black Diamond is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Biorestorative Therapies, Inc. (BRTX - Free Report) . The stock is up 6.3% year-to-date.
For Biorestorative Therapies, Inc., the consensus EPS estimate for the current year has increased 12.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Black Diamond belongs to the Medical - Biomedical and Genetics industry, a group that includes 487 individual stocks and currently sits at #146 in the Zacks Industry Rank. This group has gained an average of 4.1% so far this year, so BDTX is performing better in this area. Biorestorative Therapies, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Black Diamond and Biorestorative Therapies, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Black Diamond (BDTX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Black Diamond is a member of the Medical sector. This group includes 976 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Black Diamond is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BDTX's full-year earnings has moved 37.3% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, BDTX has returned 29% so far this year. In comparison, Medical companies have returned an average of -3%. As we can see, Black Diamond is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Biorestorative Therapies, Inc. (BRTX - Free Report) . The stock is up 6.3% year-to-date.
For Biorestorative Therapies, Inc., the consensus EPS estimate for the current year has increased 12.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Black Diamond belongs to the Medical - Biomedical and Genetics industry, a group that includes 487 individual stocks and currently sits at #146 in the Zacks Industry Rank. This group has gained an average of 4.1% so far this year, so BDTX is performing better in this area. Biorestorative Therapies, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Black Diamond and Biorestorative Therapies, Inc. as they attempt to continue their solid performance.